

5th November, 2025

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 975834 and 976560 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB: PRESS RELEASE ON UN-AUDITED FINANCIAL RESULT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025 – REGULATIONS: 30 and 51

Dear Sir,

Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, kindly find enclosed herewith Press Release on financial result for the second quarter and half year ended 30th September, 2025.

The aforesaid Press Release is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulations 46 and 62 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Kindly take the same on your record.

Thanking You,

Yours faithfully,

For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary

Encl.: As above

Dishman Carbogen Amcis Ltd. announces Q2 & H1FY26 CONSOLIDATED H1 FY26 NET REVENUE AT **RS. 13,607 million**

Ahmedabad, India – November 04 2025 – Dishman Carbogen Amcis Ltd, a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, announces their Q2 & H1 FY26 results.

Financial performance

Consolidated Q2FY26 review

- Q2FY26 Net revenue at Rs. 6,527 mn vs Rs. 7,890 mn in Q2FY25
H1FY26 Net revenue at Rs. 13,607 mn vs Rs. 13,128 mn in H1FY25
- Q2FY26 EBITDA at Rs. 1,489 mn vs Rs. 1,472 mn in Q2FY25
H1FY26 EBITDA at Rs. 2,896 mn vs Rs. 1,761 mn in H1FY25
- Q2FY26 EBITDA Margin at 22.8% vs 18.7% in Q2FY25
H1FY26 EBITDA Margin at 21.3% vs 13.4% in H1FY25

REVENUE (Rs mn)	Q2FY26	Q2FY25	YoY %	H1FY26	H1FY25	YoY %
CDMO	5,094.0	7118.7 ¹	-28.4%	11,206.4	11,333.3	-1.1%
Marketable Molecules	1,432.5	771.7	85.6%	2,400.6	1,794.9	33.7%
Grand Total	6,526.5	7,890.4		13,607.0	13,128.2	

¹1. Higher Revenue from CDMO business in Q2 2024-25 is due to postponement of one of the commercial batch shipment on customer's request and re-scheduling of some of the development projects from Q1 to Q2 to the tune of CHF 9.8 Mn in total.

Q2 & H1FY26 Result Highlights

- Net Revenue at Rs 13,607.0 mn in H1FY26 up by 3.65% YoY mainly due to higher Development revenue and higher Cholesterol and Vitamin D analogues revenue.
- CDMO revenue marginally declined by 1.1% YoY in H1FY26 primarily due to lower commercial supplies.
- CDMO revenue for Q2 FY26 is lower by 28.4% compared to Q2 FY25 mainly because of higher revenue from CDMO business in Q2 FY25 due to postponement of one of commercial batch shipment on customer's request and re-scheduling of some of the development projects from Q1 FY25 to Q2 FY25 to the tune of CHF 9.8 Mn in total.

- MM revenue increased by 85.6% QoQ and 33.7% YoY in H1FY26 primarily due to increase in cholesterol and Vitamin D analogues supplies.
- EBITDA Margin at 21.3% in H1FY26 compared to 13.4% in H1FY25 mainly due to
 - Increase in margins in CDMO segment from 19.0% to 25.3% QoQ and 14.0% to 21.3% YOY due to higher revenue contribution from late Phase III molecules.
 - Decrease in margins in MM segment from 15.7% to 14.0% QoQ is due to lower margins in quats business partially compensated by Vitamin D analogue business and increase from 9.3% to 21.4% on YoY is on account of increased focus on higher margin products and cost reduction measures.
- Net Debt excluding lease liabilities was CHF 141.43 mn as on September 30, 2025 as compared to CHF 157.6 mn as on March 31, 2025.
- Addition in Capex during the Q2 FY2026 was USD 7.3 mn and during H1FY2026 was USD 13.3 mn.

About Dishman Carbogen Amcis Ltd.

Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The Company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.

Dishman provides end-to-end integrated high-value niche CDMO offering and has comprehensive product offerings which include APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations. For details, please visit www.imdcal.com.

For details please contact:

Harshil Dalal

Group CFO

P: +91 22 22867597

E: harshil.dalal@dishmangroup.com

Krishna Patel

Ernst & Young LLP

P: +91 9998236402

E: krishna.patel2@in.ey.com